Literature DB >> 1497575

Dysfunction of the ADP/ATP carrier as a causative factor for the disturbance of the myocardial energy metabolism in dilated cardiomyopathy.

H P Schultheiss1.   

Abstract

The adenine nucleotide translocator (ADP/ATP carrier) plays a key role in nucleotide transport across the mitochondrial membrane. The quantity and function of this transport protein were investigated in myocardium from hearts with endstage failing dilated and ischemic cardiomyopathy, and were compared to measurements in nonfailing myocardium. In addition, lactate dehydrogenase (LDH) isoenzymes were determined. The concentration of the ADP/ATP carrier was significantly increased by 48% in myocardium from dilated cardiomyopathic hearts compared to control myocardium. The concentration of the carrier in explanted hearts with ischemic cardiomyopathy did not differ from values in the normal human hearts. Analysis of carrier function revealed similar nucleotide exchange rates in control hearts and hearts with ischemic cardiomyopathy, whereas carrier function was reduced in most hearts with dilated cardiomyopathy. Compared to control hearts, in hearts with dilated cardiomyopathy and decreased nucleotide exchange rate, the carrier content was significantly higher, whereas the carrier content was only slightly increased compared to control in cardiomyopathy hearts with unchanged transport activity. Compared to hearts, in dilated cardiomyopathy there was a significant increase in LDH5 and a decrease in LDH1 isoforms, indicating more anaerobic metabolism in failing dilated cardiomyopathic hearts. In summary, in hearts with dilated cardiomyopathy disturbed function of the ADP/ATP-carrier may result in altered myocardial energy metabolism and, thus, may be the cause of impaired myocardial function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1497575     DOI: 10.1007/978-3-642-72474-9_27

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  7 in total

1.  Cytoprotective role of DL-alpha-lipoic acid in cyclophosphamide induced myocardial toxicity.

Authors:  Y Mythili; P T Sudharsan; P Varalakshmi
Journal:  Mol Cell Biochem       Date:  2005-08       Impact factor: 3.396

2.  Comparative study of disease progression for heart failure with different etiologies via time-ordered network analysis.

Authors:  Haoran Sun; Xiuhong Li; Hao Yuan; Chengyi Wang; Guangde Zhang; Hongbo Shi
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 3.  Mitochondria in the human heart.

Authors:  H Lemieux; C L Hoppel
Journal:  J Bioenerg Biomembr       Date:  2009-04       Impact factor: 2.945

Review 4.  Mitochondria in cardiac hypertrophy and heart failure.

Authors:  Mariana G Rosca; Bernard Tandler; Charles L Hoppel
Journal:  J Mol Cell Cardiol       Date:  2012-09-13       Impact factor: 5.000

Review 5.  Mitochondrial dysfunction in heart failure.

Authors:  Mariana G Rosca; Charles L Hoppel
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

Review 6.  The mitochondrial ADP/ATP carrier: functional and structural studies in the route of elucidating pathophysiological aspects.

Authors:  Véronique Trézéguet; Ludovic Pélosi; Guy J M Lauquin; Gérard Brandolin
Journal:  J Bioenerg Biomembr       Date:  2008-11-01       Impact factor: 3.853

7.  Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis.

Authors:  Suping Zhang; Futian Tang; Yuhong Yang; Meili Lu; Aina Luan; Jing Zhang; Juan Yang; Hongxin Wang
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.